指南与共识肺外科

2026年美国胸外科医师协会(AATS)早期非小细胞肺癌分期与多学科管理专家共识修订版解读

2026 Revised recommendations of the American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer.
指南 / 共识 · J Thorac Cardiovasc Surg · 2026-09-25

该修订版基于新出现的随机试验证据,更新了早期非小细胞肺癌在分期诊断、新辅助治疗、手术管理及术后治疗方面的推荐。关键修改包括支持术前或围术期化学免疫治疗、辅助靶向治疗及辅助免疫治疗的实践标准演变,并继续强调分子诊断与多学科评估。

要点

  • 新辅助或围术期化学免疫治疗获额外随机试验支持,推荐用于可切除早期非小细胞肺癌。
  • 符合条件的患者应接受辅助靶向治疗,辅助免疫治疗实践标准有所更新。
  • 强调分子诊断及多学科评估在非转移性患者诊疗中的核心作用。

核心结论

  • 修订版共识基于新随机试验证据,细化了早期非小细胞肺癌的分期诊断、新辅助治疗、手术管理及术后治疗标准。
  • 新增证据支持术前或围术期化学免疫治疗的疗效,并更新了辅助靶向及辅助免疫治疗的推荐。
  • 继续强调对非转移性患者进行准确诊断分期、分子检测及多学科评估的必要性。

研究设计与样本

  • 美国胸外科医师协会(AATS)基于2023年专家共识文件及后续发表的新证据制定的修订版专家共识。

主要发现

  • 新增随机试验支持术前或围术期化学免疫治疗的有效性。
  • 辅助靶向治疗适用于符合条件的患者。
  • 辅助免疫治疗在既往未治疗患者中的实践标准正在演变。

临床怎么用

  • 对可切除早期非小细胞肺癌,应考虑术前或围术期化学免疫治疗。
  • 对符合条件的患者应进行辅助靶向治疗,并关注辅助免疫治疗的更新标准。
  • 诊疗过程中应重视分子诊断和多学科团队评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diagnosis, staging, and treatment of early-stage lung cancer remains an important area of thoracic surgical oncology. The previous American Association for Thoracic Surgery Expert Consensus Document, published in 2023, reflected critical recommendations for the workup and management of this disease, including the adoption of chemoimmunotherapy as standard of care for patients with locally advanced disease without targetable mutations. Since that publication, there have been additional publications that provide further insight into the management of these patients. This revised document seeks to refine best practice standards in regard to staging and diagnosis, neoadjuvant treatment, surgical management, and postoperative therapy of these patients based on the currently available data. Key modifications made to the previous version reflect additional randomized trials supporting the efficacy of preoperative or perioperative chemoimmunotherapy, adjuvant targeted therapy for eligible patients, and evolving practice standards regarding adjuvant immunotherapy for previously untreated patients. In addition, the current document continues to support the critical need for accurate diagnosis and staging of patients with nonmetastatic disease, including an emphasis on molecular diagnostics, as well as multidisciplinary evaluation of patients who are eligible for multi-modality treatment.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Kidane B, Bott M, Spicer J, et al. 2026 Revised recommendations of the American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer. J Thorac Cardiovasc Surg. 2026. PMID: 42790620. doi:10.1016/j.jtcvs.2026.08.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。